See more : Entero Therapeutics, Inc. (ENTO) Income Statement Analysis – Financial Results
Complete financial analysis of AFT Pharmaceuticals Limited (AFT.NZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AFT Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Walnut Capital Limited (0905.HK) Income Statement Analysis – Financial Results
- Integrated Rail and Resources Acquisition Corp. (IRRX) Income Statement Analysis – Financial Results
- CHO Pharma, Inc. (6586.TWO) Income Statement Analysis – Financial Results
- Allegiance Bancshares, Inc. (ABTX) Income Statement Analysis – Financial Results
- Hargreaves Lansdown plc (HRGLF) Income Statement Analysis – Financial Results
AFT Pharmaceuticals Limited (AFT.NZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.aftpharm.com
About AFT Pharmaceuticals Limited
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195.41M | 155.82M | 129.83M | 112.86M | 105.24M | 84.87M | 79.88M | 69.05M | 57.67M | 56.24M | 48.94M | 40.36M |
| Cost of Revenue | 107.14M | 83.66M | 68.54M | 64.36M | 57.33M | 44.40M | 45.88M | 43.21M | 36.43M | 35.08M | 28.61M | 22.73M |
| Gross Profit | 88.27M | 72.16M | 61.30M | 48.50M | 47.91M | 40.48M | 34.00M | 25.84M | 21.24M | 21.16M | 20.33M | 17.64M |
| Gross Profit Ratio | 45.17% | 46.31% | 47.21% | 42.97% | 45.52% | 47.69% | 42.57% | 37.42% | 36.83% | 37.62% | 41.54% | 43.69% |
| Research & Development | 8.09M | 5.65M | 5.51M | 3.44M | 1.98M | 2.59M | 8.23M | 11.23M | 7.29M | 5.76M | 3.91M | 3.33M |
| General & Administrative | 11.22M | 11.12M | 7.77M | 7.78M | 9.11M | 7.20M | 8.31M | 5.85M | 6.13M | 5.48M | 1.35M | 1.03M |
| Selling & Marketing | 45.26M | 36.54M | 28.33M | 27.44M | 26.20M | 26.54M | 28.53M | 25.96M | 17.69M | 18.30M | 6.58M | 5.12M |
| SG&A | 56.47M | 47.67M | 36.10M | 35.22M | 35.31M | 33.74M | 36.84M | 31.82M | 23.82M | 23.77M | 15.77M | 12.47M |
| Other Expenses | 0.00 | -189.00K | 1.43M | 1.49M | 10.68M | 2.49M | 2.42M | 2.82M | 2.07M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 64.04M | 55.04M | 41.61M | 39.76M | 38.08M | 36.65M | 45.41M | 43.37M | 33.47M | 32.41M | 20.56M | 16.72M |
| Cost & Expenses | 171.18M | 138.70M | 110.15M | 104.13M | 95.41M | 81.05M | 91.29M | 86.58M | 69.90M | 67.49M | 49.17M | 39.45M |
| Interest Income | 66.00K | 13.00K | 4.00K | 4.00K | 22.00K | 42.00K | 125.00K | 347.00K | 262.16K | 1.91M | 939.00K | 609.00K |
| Interest Expense | 3.69M | 2.87M | 2.44M | 3.44M | 8.05M | 8.42M | 2.65M | 3.88M | 1.82M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.01M | 1.72M | 1.04M | 1.10M | 1.10M | 319.00K | 340.00K | 326.00K | 268.00K | 202.00K | 203.00K | 185.00K |
| EBITDA | 27.72M | 20.40M | 21.12M | 12.43M | 21.04M | 3.96M | -9.67M | -14.42M | -9.32M | -5.76M | 3.41M | 3.00M |
| EBITDA Ratio | 14.18% | 13.09% | 16.27% | 11.02% | 20.63% | 7.63% | -12.11% | -20.46% | -17.64% | -10.25% | 6.97% | 7.43% |
| Operating Income | 24.24M | 18.67M | 20.08M | 11.33M | 20.93M | 6.16M | -10.01M | -14.45M | -10.44M | -5.97M | 3.21M | 2.81M |
| Operating Income Ratio | 12.40% | 11.98% | 15.46% | 10.04% | 19.89% | 7.26% | -12.54% | -20.93% | -18.10% | -10.61% | 6.56% | 6.97% |
| Total Other Income/Expenses | -2.22M | -1.33M | -1.70M | -1.09M | -8.33M | -6.34M | -1.26M | -960.00K | 533.00K | -7.19M | -2.25M | -2.51M |
| Income Before Tax | 22.02M | 15.80M | 18.69M | 7.89M | 12.88M | -2.26M | -12.67M | -18.33M | -11.99M | -13.16M | -1.17M | 306.00K |
| Income Before Tax Ratio | 11.27% | 10.14% | 14.39% | 6.99% | 12.24% | -2.66% | -15.86% | -26.55% | -20.79% | -23.39% | -2.39% | 0.76% |
| Income Tax Expense | 6.41M | 5.15M | -1.16M | 105.00K | 185.00K | 168.00K | 58.00K | 58.00K | -37.84K | 282.00K | 59.00K | 134.00K |
| Net Income | 15.61M | 10.65M | 19.85M | 7.78M | 12.69M | -2.43M | -12.72M | -18.39M | -11.95M | -12.87M | -1.11M | 172.00K |
| Net Income Ratio | 7.99% | 6.84% | 15.29% | 6.90% | 12.06% | -2.86% | -15.93% | -26.63% | -20.73% | -22.89% | -2.27% | 0.43% |
| EPS | 0.15 | 0.10 | 0.19 | 0.07 | 0.12 | -0.02 | -0.13 | -0.19 | -0.43 | -0.18 | -0.02 | 0.00 |
| EPS Diluted | 0.15 | 0.10 | 0.19 | 0.07 | 0.12 | -0.02 | -0.13 | -0.19 | -0.43 | -0.18 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 104.87M | 104.85M | 104.68M | 103.30M | 97.31M | 97.31M | 97.25M | 96.84M | 27.57M | 73.14M | 74.40M | 74.43M |
| Weighted Avg Shares Out (Dil) | 104.87M | 104.85M | 104.68M | 103.30M | 97.31M | 97.31M | 97.25M | 97.11M | 27.58M | 73.14M | 74.40M | 74.40M |
Source: https://incomestatements.info
Category: Stock Reports